Kristen Hege, Member Board of Directors at KSQ Therapeutics, Inc., shared a post on LinkedIn:
“So fun to ring the opening bell at the NYSE with so many friends and colleagues from Society for Immunotherapy of Cancer (SITC). Here’s to our audacious goal of 100 new cancer immunotherapies approved for patients over the next decade.”
Other articles featuring Kristen Hege on OncoDaily.